Skip to main content


Friday, April 19th, 2024

6:00 – 9:30 PM Registration
7:00 PM Welcome Address Dr. Christian Kollmannsberger, GUTG Chair
7:10 – 9:30 PM Welcome Dinner Reception English Bay Room

Saturday, April 20th, 2024

All Sessions Include 25% of Time for Question Periods and Audience Participation 

7:00 – 8:00 AM Breakfast English Bay Room
8:00 – 8:05 AM Welcoming Remarks for Day 1 Dr. Krista Noonan – GUTG Systemic Chair
Grand Ballroom

Prostate Session 1: Localized PC

Session Chairs: Dr. Cal Andreou, Dr. Ryan Urban
8:00 – 8:20 AM Localized High Risk Prostate Cancer: Is There a Role for Neoadjuvant Treatment? Dr. Miles Mannas
8:20 – 8:40 AM Panel: Multidisciplinary Care for High Risk Localized Prostate Cancer: Local Treatment and Adjuvant Therapy Dr. Mira Keyes,
Dr. Nathan Wong
8:40 – 9:00 AM Non-Metastatic Biochemical Recurrence After Local Therapy for Prostate Cancer: Novel Treatment Options and Multidisciplinary Care Dr. Michael Peacock
9:00 – 9:20 AM Management of ARPis: Toxicity Management and Practical Application Dr. Sunil Parimi
9:20 – 9:40 AM Genetic Testing in Prostate Cancer: Latest Updates Dr. Alex Wyatt

Special Session: Radiopharmaceutical Treatments for Prostate Cancer

Session Chairs: Dr. Param Bains, Dr. James Curtis, Dr. Stacy Miller
9:40 – 9:55 AM PSMA PET: Indications and Future Use Dr. Patrick Martineau
9:55 – 10:10 AM Delivery / Management – State of Affairs in BC Dr. Don Wilson
10:10 – 10:15 AM Panel Discussion and Q&A Period Dr. Patrick Martineau, Dr. Don Wilson
10:15 – 10:30 AM Health Break & Networking English Bay Room

RCC Session

Session Chairs: Dr. Soha Atallah, Dr. Samrad Ghavimi, Dr. Ed Hardy
10:35 – 10:55 AM DEBATE: Adjuvant Pembro in High Risk RCC: Is There an Ideal Patient?
– Yes, All Patients Should Be Treated
– No, Only Selected Patients Should Be Treated
Yes – Dr. Simon Yu
No – Dr. Adam Fundytus
10:55 – 11:15 AM IO-Refractory RCC: Management Options Dr. Aleksi Suo
11:15 – 11:35 AM Pathologic and Molecular Classification of RCC: Update on New Subtypes Dr. Gang Wang
11:35 – 11:55 AM Hereditary Kidney Cancer Syndromes Dr. Daniel Araujo
11:55 – 12:15 PM First Line Treatment of Non-Clear Cell RCC: Therapeutic Choices and Management Dr. Daygen Finch
12:15 – 1:00 PM Lunch / Networking / Exhibition English Bay Room
1:00 – 1:20 PM Special Session: Future of Cancer Care in BC Dr. Kim Chi
1:20 – 1:30 PM Question & Answer Period

Testis / Penile Cancer Session

Session Chairs: Dr. Iain McAuley, Dr. Jesse Shustik, Dr. Justin Owen
1:30 – 1:50 PM Management of Postchemotherapy Residual Retroperitoneal / Retrocrural Masses in Germ Cell Cancer Dr. Matthew Ho
1:50 – 2:10 PM Management of Postchemotherapy Residual Thoracic / Mediastinal Masses Dr. Alexander Lee
Penile Cancer
2:10 – 2:25 PM Surgery Dr. Nathan Wong
2:25 – 2:40 PM Advances in Radiotherapy for Penile Cancer Dr. Juanita Crook
2:40 – 2:55 PM Medical Oncology Dr. Michael Humphreys
2:55 – 3:10 PM Discussions Dr. Nathan Wong, Dr. Juanita Crook, Dr. Michael Humphreys
3:10 – 3:15 PM Closing Remarks for Day 1 Dr. Nathan Hoag, BCUS Chair
7:00 PM – 9:30PM BCGU Dinner
Keynote: Artificial Intelligence & Medicine: Best Practices and Trustworthy Ecosystems
Dr. Arman Rahmim, University of British Columbia
Grand Ballroom

Sunday, April 21st, 2024

All Sessions Include 25% of Time for Question Periods and Audience Participation 

7:00 – 8:00 AM Breakfast English Bay Room
8:00 – 8:05 AM Welcoming Remarks for Day 2 Dr. Jack Zheng – GURG RT Chair
Grand Ballroom

Bladder Cancer Session

Session Chairs: Dr. Alym Abdulla, Dr. Ardashes Avanessian, Dr. David Kim
8:05 – 8:25 AM Non-Muscle Invasive Bladder Cancer: Are We Making Progress? Dr. Brian Yang
8:25 – 8:45 AM PANEL: Bladder Preservation/Active Surveillance After Neoadjuvant Therapy in MIBC Panelists: Dr. Marie-Pier St-Laurent &
Dr. Clement Ho
8:45 – 9:05 AM DEBATE: EV-Pembro / Cis-Gem-Nivo as First Line Treatment for Cis-Eligible Patient: What is the Preferred Treatment for Cisplatin Eligible, Cisplatin-Ineligible and Platinum Ineligible?

– EV/Pembro for All
– Gem/Cis/Nivo Still Has a Place

EV/Pembro: Dr. Richard Gagnon
Cis/Gem/Nivo: Dr. Susan Ellard
9:05 – 9:25 AM Later Line Treatment of Urothelial Cancer in an Evolving First-Line Landscape Dr. Jean-Michel Lavoie
9:25 – 9:45 AM Is There a Role for Radiation in Oligometastatic / Locally Recurrent UC? Dr. Tina Zhang
9:45 – 10:05 AM Appropriate Peri-Operative Systemic Treatment of Non-Urothelial Bladder Cancers Dr. Bernie Eigl
Special Session
Session Chair: Dr. Chris Hoag
10:05 – 10:25 AM Surgical Quality Assurance for Cancer Care with an Emphasis on GU Cancers Dr. Carl Brown
10:25 – 10:50 AM Health Break / Networking / Exhibition / Check-out
English Bay Room

Prostate Cancer Session 2: mCRPC

Session Chairs: Dr. Andrew Bang, Dr. Jaco Fourie, Dr. Jeffrey McCracken
10:50 – 11:10 AM Targeting the AR in Metastatic PC: Is it Still a Target? Dr. Lucia Nappi
11:10 – 11:30 AM mCRPC: Treatment Sequencing in the Era of Radioligand Therapies and PARP Inhibitor Combinations Dr. Jasna Deluce
11:30 – 11:50 AM Metastatic Prostate Cancer: Novel Targets and Therapeutic Options on the Horizon Dr. Corinne Maurice-Dror
11:50 – 12:10 PM Radiotherapy to Prostate in Metastatic Prostate Cancer Dr. Hamid Raziee
12:10 – 12:15 PM BCGU Conference Closing Remarks Dr. Christian Kollmannsberger, GUTG Chair

Special Session – GU Biobank

Session Chairs: Dr. Kim Chi, Dr. Corinne Maurice-Dror, Dr. Lucia Nappi, Dr. Alex Wyatt, Dr. Gillian Vandekerkhove
Grand Ballroom
12:30 – 12:40 PM GUBB Introduction GUBB Co-Directors: Dr. Corinne Maurice Dror & Dr. Gillian Vandekerkhove
12:40 – 12:45 PM Rolling Circle Amplification to Improve miR371 Detection in Patients with Early Stage GCT Andy Jia
12:45 – 12:50 PM Biosensor Technology to Predict Tumor Recurrence in Patients With Early GCT Dr. Sajjad Janfaza
12:50 – 12:55 PM Circulating miRNAs Analysis to Predict Immune Response in mRCC Patients Dr. Guliz Ozgun
12:55 – 1:00 PM Prediction of Plasma ctDNA Fraction and Prognostic Implications of Liquid Biopsy in Advanced Prostate Cancer Dr. Cameron Herberts
1:00 – 1:05 PM ctDNA-FGFR Status as a Predictive Biomarker for FGFR Targeted Therapy in Urothelial Cancer Dr. Gillian Vanderkerkhove
1:05 – 1:10 PM The Prevalence of Clonal Hematopoiesis in Metastatic Genitourinary Cancers Dr. Asli Munzur
1:10 – 1:40 PM Discussion and Future Directions
1:40 PM Closing Remarks